Do you take into account ALK fusion variants in your practice for deciding treatment for NSCLC?

EML4-ALK v3 subtypes and TP53 co-mutations tend to be associated with shorter overall survival in patients, and while we take note of these molecular changes, they have not yet been affected by the selection of frontline therapy. I pay attention to ALK mutations, specifically the G1202R mutation, wh...

I use comprehensive NGS (ideally RNA-seq) to identify ALK fusions upfront because it reliably detects partners/variants, but I treat all ALK+ NSCLC patients with next-gen TKIs (alectinib, brigatinib, or lorlatinib) first line regardless of the specific variant. Robust clinical trial data (ALEX, CROW...

I do not. I think they are all sensitive just more so or less so. I am mindful of it but I currently don’t change therapy. I am mindful of this for sure, but don’t do anything different right now.